Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Jago collaborating on extended-release zileuton (Zyflo) for asthma; 1998 NDA is planned.

Executive Summary

ABBOTT/JAGO TWICE-DAILY ZILEUTON NDA FOR ASTHMA SLATED FOR 1998, Jago's parent company SkyePharma disclosed Jan. 20. Jago, acquired by SkyePharma in May, is collaborating with Abbott on an extended-release formulation of Abbott's recently launched leukotriene inhibitor Zyflo (zileuton). The Geomatrix formulation of zileuton is "entering Phase III clinical studies" and "a submission for regulatory approval is expected to be made in 1998," SkyePharma said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel